Rigel Pharmaceuticals (RIGL -2.22%) was kicked in the stomach earlier this month, when AstraZeneca (AZN 5.38%) returned full rights for fostamatinib. The Big Pharma member decided to write off $140 million of assets attributed to the partnership rather than take the next steps in commercializing the drug for rheumatoid arthritis. Ouch. While it's a smart idea for AstraZeneca to walk away now, Rigel is in a tough spot with its top drug candidate receiving a vote of no confidence. There is a handful of companies that stand to benefit from fostamatinib's failure. In the following video, Fool contributor Maxx Chatsko explains what it means for investors and what the future could hold for the development-stage company.